CytomX Therapeutics, Inc. (CTMX): who owns it and who trades it
As of Nov 16, 2026, CTMX insiders reported 5 open-market sales worth $1.2M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sean A. McCarthy (CEO), with $764K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling CytomX Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CTMX
179 funds and institutions reported CTMX shares worth $802M at the end of Q2 2026, about 98% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 98%Everyone else 2%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 32.71M | 15.03% | $123M | +2% |
| Kynam Capital Management, LP | 21.70M | 9.97% | $81.4M | +45% |
| BlackRock, Inc. | 17.56M | 8.07% | $65.8M | +236% |
| Bank of America Corp | 15.08M | 6.93% | $56.6M | +48% |
| State Street Corp | 11.75M | 5.40% | $44.1M | +107% |
| Perceptive Advisors LLC | 10.44M | 4.80% | $39.1M | +3% |
| Vanguard Capital Management LLC | 8.53M | 3.92% | $32M | -2% |
| Point72 Asset Management, L.P. | 7.81M | 3.59% | $29.3M | -1% |
| Wellington Management Group LLP | 5.17M | 2.37% | $19.4M | +44% |
| Venrock Adviser, LLC | 4.98M | 2.29% | $18.7M | -50% |
| Baker Bros. Advisors LP | 4.98M | 2.29% | $18.7M | No change |
| Geode Capital Management, LLC | 4.68M | 2.15% | $17.5M | +126% |
| Elmind Capital, LP | 4.55M | 2.09% | $17.1M | No change |
| Nextech Invest Ltd. | 4.45M | 2.04% | $16.7M | No change |
| Two Sigma Investments, LP | 4.13M | 1.90% | $15.5M | +52% |
| Eversept Partners, LP | 3.56M | 1.63% | $13.3M | +12% |
| UBS Group AG | 3.47M | 1.59% | $13M | +11% |
| Siren, L.L.C. | 3.46M | 1.59% | $13M | No change |
| ADAR1 Capital Management, LLC | 3.37M | 1.55% | $12.6M | -1% |
| Citadel Advisors LLC | 3.11M | 1.43% | $11.7M | -42% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CTMX insiders reported $0 of open-market purchases and $1.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogden | CFO | Sale | 1,624 | $3.05 | $5K | Form 4 |
| Mar 17, 2026 | Yu-Waye Chu | Chief Medical Officer | Sale | 21,279 | $6.42 | $137K | Form 4 |
| Mar 17, 2026 | Sean A. McCarthy | CEO | Sale | 118,969 | $6.42 | $764K | Form 4 |
| Mar 17, 2026 | Marcia Belvin | Vice president | Sale | 31,492 | $6.42 | $202K | Form 4 |
| Mar 17, 2026 | Christopher Ogden | CFO | Sale | 19,323 | $6.42 | $124K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sean A. McCarthy | CEO, Director | – | $764K | Mar 17, 2026 |
| Marcia Belvin | SVP, Chief Scientific Officer | – | $202K | Mar 17, 2026 |
| Yu-Waye Chu | Chief Medical Officer | – | $137K | Mar 17, 2026 |
| Christopher Ogden | Chief Financial Officer | – | $129K | Jun 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CTMX short interest
Very high short interest. 20.8% of CTMX shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 45%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 45.25M CTMX shares were sold short, 20.8% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 3.77M shares, buying them all back would take about 12.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 45.25M | 20.77% | +6% | 3.77M | 12.0 |
| Oct 15, 2026 | 42.79M | 19.64% | +5% | 3.11M | 13.8 |
| Sep 30, 2026 | 40.81M | 18.73% | +6% | 4.70M | 8.7 |
| Sep 15, 2026 | 38.64M | 17.73% | +15% | 4.16M | 9.3 |
| Aug 31, 2026 | 33.51M | 15.38% | -3% | 2.84M | 11.8 |
| Aug 14, 2026 | 34.62M | 15.89% | -1% | 2.17M | 15.9 |
| Jul 31, 2026 | 35.11M | 16.11% | -13% | 2.98M | 11.8 |
| Jul 15, 2026 | 40.32M | 18.52% | +13% | 3.89M | 10.4 |
| Jun 30, 2026 | 35.57M | 16.34% | +16% | 8.23M | 4.3 |
| Jun 15, 2026 | 30.61M | 14.06% | +7% | 3.54M | 8.7 |
| May 29, 2026 | 28.72M | 13.19% | -8% | 3.09M | 9.3 |
| May 15, 2026 | 31.13M | 14.30% | +5% | 3.02M | 10.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
CytomX Therapeutics company events
CytomX Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 27, 2026LeadershipCharles Fuchs, M.D., M.P.H., was appointed to the Board of Directors of CytomX Therapeutics, Inc., effective immediately, as a Class II director, with an initial term expiring at the Company’s 2029 annual meeting of stockholders. Filing
- Jun 22, 2026LeadershipStockholders of CytomX Therapeutics, Inc. approved at the Company’s 2026 Annual Meeting of Stockholders an amendment to the Company’s Amended and Restated 2015 Equity Incentive Plan and an amendment to the Company’s Amended and Restated Employee Stock Purchase Plan. Filing
- Jun 3, 2026AgreementCytomX Therapeutics, Inc. previously entered into that certain Collaboration and License Agreement, effective November 16, 2022 (as amended, the “Agreement”), with Regeneron Pharmaceuticals, Inc., providing for the collaboration on the creation of conditionally-activated investigational bispecific… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 19, 2026AnnouncementCytomX Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, in connection with the offering, issuance and sale by the Company of 45,990,567 shares of the Company’s… Filing
- Mar 16, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
CytomX Therapeutics financials
Famous investors that hold CTMX
4 of the 50 well-known investors we track reported holding CTMX in their latest 13F filing. The largest position is Steve Cohen's, worth $23.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 8.60M | $23.4M | 0.0% | +10% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 7.01M | $19.1M | 0.0% | +125% |
| Israel Englander · Millennium Management | Q3 2026 | 263,898 | $718K | 0.0% | -84% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 187,071 | $509K | 0.0% | -86% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CTMX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.1% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.1% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 5.4% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 5.4% |
Questions about CytomX Therapeutics, Inc. (CTMX) stock
Who owns the most CTMX stock?
The largest reported owner of CytomX Therapeutics, Inc. (CTMX) is FMR LLC (Fidelity), with 15.0% of the company. In total, 179 funds and institutions reported holding CTMX at the end of Q2 2026, together about 98% of the shares. See the largest owners.
Are CTMX insiders buying or selling?
In the last 12 months, CTMX insiders reported no open-market purchases and 5 sales worth $1.2M. The latest trade was on Jun 15, 2026. See every trade.
What is the short interest in CTMX?
As of Oct 30, 2026, 45.25M CTMX shares were sold short, 20.8% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 3.77M shares, buying them all back would take about 12.0 trading days (days to cover). See the history.
Which famous investors hold CTMX?
4 of the 50 well-known investors we track reported CTMX in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $23.4M. See all holders.
Executive pay
CytomX Therapeutics's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, up 170% from $1.8M the year before. In the last 12 months, CytomX Therapeutics's executives and directors bought no stock on the open market and sold $1.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.